Multiple

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Retrieved on: 
Wednesday, March 27, 2024
Multiple, Professor, ETV, SAN, Patient, Hepatology, Southern Medical University, SHBG, Doctor of Science, University, Doctor of Philosophy, MBBS, MASH, MBA, Science, Therapy, Hepatitis, Part, Division, University of Hong Kong, Infection, CHB, Pharmaceutical industry

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

Key Points: 
  • The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
  • “We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024.
  • We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers.

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Retrieved on: 
Tuesday, March 26, 2024
GAAP, Research, GBA1, Multiple, Therapy, G&A, Safety

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update.

Key Points: 
  • BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update.
  • We believe our cash position and operational plans are strong and allow us to meet our near-term milestones,” said Matthias Alder, Gain Therapeutics’ CEO.
  • Research and development (R&D) expenses increased by $3.1 million to $11.5 million for the year ended December 31, 2023, from $8.4 million for the year ended December 31, 2022.
  • Net loss as of December 31, 2023 included non-cash compensation expenses of $3.3 million as compared to 2022 non-cash compensation expenses of $1.5 million.

Auto Dealership Buy/Sell Market Achieves New Transaction Record in 2023, Surpassing 2021 Peak; Valuations Remain at All Time Highs for Top Franchises in High Growth Markets

Retrieved on: 
Tuesday, April 9, 2024
Consulting, EV, Electric Vehicles, Automotive, Professional Services, Business, Marketing, Advertising, Communications, Other Automotive, General Automotive, Finance, Lincoln, Volvo, Face, Growth, Asbury Automotive Group, Original equipment manufacturer, Big Three (automobile manufacturers), Partnership, Risk, Multiple, Kerrigan, Sale, Acquisition, Ford, ICE, BMW, OEM, Toyota Financial Services, Population growth, Car dealership

The auto dealership buy/sell market’s outperformance relative to the broader corporate M&A market is, according to the report, a result of its distinctly private structure.

Key Points: 
  • The auto dealership buy/sell market’s outperformance relative to the broader corporate M&A market is, according to the report, a result of its distinctly private structure.
  • “When earnings soared in 2021, buyers correctly projected that pandemic earnings were unsustainable and normalized earnings for valuation purposes.
  • The public dealership groups acquired 61 franchises for $2.7 billion in 2023, the second highest US acquisition spending level on record.
  • The Kerrigan Auto Retail Index is designed to track dealership valuation trends, while also providing key insights into factors influencing auto retail.

Artmarket.com: the Artprice100© index was up 1.55% in 2023

Retrieved on: 
Thursday, April 4, 2024
Surrealism, Print, Annual report, ROI, Art market, Old Master, Multiple, Fine art, Female, Sale, Suggestion, Euronext Paris, Artprice, Contemporary art, Century

"Artprice's latest annual report, "The Art Market in 2023" underscores the shift from a sellers' market to a buyers' market in 2023, explains thierry Ehrmann, CEO and Founder of Artmarket.com and its Artprice department.

Key Points: 
  • "Artprice's latest annual report, "The Art Market in 2023" underscores the shift from a sellers' market to a buyers' market in 2023, explains thierry Ehrmann, CEO and Founder of Artmarket.com and its Artprice department.
  • The exact breakdown of the portfolio as of 1 January 2023 is provided below in the section Composition of Artprice100© as of 1 January 2023.
  • The investment in works by Jean-Michel Basquiat (1960-1988) represented 3.9% of the portfolio at the start of 2023, but his price index fell by -15% in 2023.
  • Modern Art remained the largest segment in the composition of the Artprice100© index, accounting for 43% of the initial 2023 investment.

Artmarket.com: the Artprice100© index was up 1.55% in 2023

Retrieved on: 
Thursday, April 4, 2024
Surrealism, Print, Annual report, ROI, Art market, Old Master, Multiple, Fine art, Female, Sale, Suggestion, Euronext Paris, Artprice, Contemporary art, Century

"Artprice's latest annual report, "The Art Market in 2023" underscores the shift from a sellers' market to a buyers' market in 2023, explains thierry Ehrmann, CEO and Founder of Artmarket.com and its Artprice department.

Key Points: 
  • "Artprice's latest annual report, "The Art Market in 2023" underscores the shift from a sellers' market to a buyers' market in 2023, explains thierry Ehrmann, CEO and Founder of Artmarket.com and its Artprice department.
  • The exact breakdown of the portfolio as of 1 January 2023 is provided below in the section Composition of Artprice100© as of 1 January 2023.
  • The investment in works by Jean-Michel Basquiat (1960-1988) represented 3.9% of the portfolio at the start of 2023, but his price index fell by -15% in 2023.
  • Modern Art remained the largest segment in the composition of the Artprice100© index, accounting for 43% of the initial 2023 investment.

Puffshot E-Cigarettes Triumph with Prestigious 2024 Design Awards, Redefining Vaping Experience

Retrieved on: 
Tuesday, April 2, 2024
Temperature, Taste, Consciousness, Multiple, Inhalation, Child, Cart, Safety, Tobacco

HOUSTON, April 2, 2024 /PRNewswire/ -- Puffshot, a leading e-cigarette brand, has proudly announced its latest achievement in the international design arena, having recently won the renowned French Design Gold Award and the American Good Design Award for 2024.

Key Points: 
  • HOUSTON, April 2, 2024 /PRNewswire/ -- Puffshot, a leading e-cigarette brand, has proudly announced its latest achievement in the international design arena, having recently won the renowned French Design Gold Award and the American Good Design Award for 2024.
  • These prestigious recognitions highlight Puffshot's commitment to innovation and excellence in design, underscoring the brand's significant impact within the global design community.
  • With a "Collect and Deliver" new design and 5x reinforced vaping experience, it sets new standards in taste preference consistency.
  • Today, Puffshot, with its unique charm and innovative spirit, is redefining the vaping experience and leading a new trend in the e-cigarette industry.

Nuvei enters into agreement to be taken private by Advent International, alongside existing Canadian shareholders Philip Fayer, Novacap and CDPQ at a price of US$34.00 per share

Retrieved on: 
Monday, April 1, 2024
Hierarchy, Multiple, Special, History, Bank statement, BMO Capital Markets, Partnership, Committee, Minority, Risk, EDGAR, Toronto Stock Exchange, Head, Advent International, Arrangement, Willkie Farr & Gallagher, Related, Kirkland & Ellis, Schedule, Blake, Cassels & Graydon, CDPQ, Regulation, Meeting, TSX, Canada Business Corporations Act, RBC Capital Markets, E-commerce, Norton Rose Fulbright, Growth, LLP, Security (finance)

MONTREAL, April 1, 2024 /PRNewswire/ -- Nuvei Corporation ("Nuvei" or the "Company") (Nasdaq: NVEI) (TSX: NVEI), today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") to be taken private by Advent International ("Advent"), one of the world's largest and most experienced global private equity investors, with the support of each of the Company's holders of multiple voting shares ("Multiple Voting Shares"), being Philip Fayer, certain investment funds managed by Novacap Management Inc. (collectively, "Novacap") and CDPQ, via an all-cash transaction which values Nuvei at an enterprise value of approximately US$6.3 billion. The Company will continue to be based in Montreal.

Key Points: 
  • Nuvei will benefit from the significant resources, operational, and sector expertise, as well as the capacity for investment provided by Advent.
  • Philip Fayer will remain Nuvei's Chair and Chief Executive Officer and will lead the business in all aspects of its operations.
  • Fayer continued: "Our strategic initiatives have always focused on accelerating our customers revenue, driving innovation across our technology, and developing our people.
  • Bringing in a partner with such extensive experience in the payments sector will continue to support our development."

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Retrieved on: 
Tuesday, February 27, 2024
SAD, Glucocerebrosidase, Safety, Single, Therapy, AFL, Clinical trial, Plasma, GBA1, Multiple

Following the HREC approval, administration of GT-02287 in the MAD part of the study has been initiated.

Key Points: 
  • Following the HREC approval, administration of GT-02287 in the MAD part of the study has been initiated.
  • “Our Phase 1 clinical trial of GT-02287 remains on track and according to plan,” said Matthias Alder, Chief Executive Officer of Gain Therapeutics.
  • Compelling preclinical data presented at WORLDSymposium™ earlier in February 2024 demonstrated that treatment with GT-02287 completely restored motor function and reduced plasma levels of the emerging neurodegeneration biomarker NfL back to normal levels.
  • Based on these data, GT-02287 may have the potential to slow or even stop the progression of Parkinson’s disease.

Labroots Hosts 12th Annual Neuroscience Online Event Scheduled on March 6, 2024

Retrieved on: 
Thursday, February 29, 2024
SVKM's NMIMS, Pennsylvania State University, Artificial intelligence, DSM-IV codes, University, Kellogg School, Behavior, Diagnosis, Health, Labroots, Associate, Gubra, Panel discussion, Bangladesh Technical Education Board, Networking hardware, Blood test, Translation, Ethics, NIH, Computer, Data collection, Aarhus University, Associate professor, Initiative, BRAIN, Dementia, Brain, Parkinson's disease, Natural language processing, University of Pennsylvania, Language, Drug discovery, BRAIN Initiative, Neurodegenerative disease, Thought, Social behavior, Heart, Translational neuroscience, Lewy body, Research, Multiple, Neural engineering, Collection, MD, Discovery, Depression, Medical imaging

YORBA LINDA, Calif., Feb. 29, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its free 12th annual event in the Neuroscience Virtual Event Series to be held on March 6, 2024. Marking a decade of sharing ground breaking research and scientific discovery via Labroots' immersive platform, this dynamic event continues its tradition of showcasing some of the brightest minds at the forefront of neuroscience impacting health and disease today.

Key Points: 
  • I am excited to discuss this at Labroots' 12th annual event in the Neuroscience Virtual Event Series."
  • Hosted by Labroots and produced on Chati, participants in the event can connect seamlessly across desktop and mobile devices while engaged in a one-stop educational experience.
  • Remember to use the hashtag #LRneuro to follow the conversation and connect with other members of the global Neuroscience community!
  • Follow @Neuroscience_LR on Twitter and @Neuroscience.LR on Facebook to stay up to date with the latest Trending News in Neuroscience.

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Retrieved on: 
Tuesday, January 30, 2024
Senior, Angiogenesis, Patient, PALO, ABC, Clinical research, University, Outline, Partner (business rank), Safety, Disease, Diabetic retinopathy, Therapy, Inflammation, KOD, Retina, Multiple, DME, Vaccine

PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.

Key Points: 
  • PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.
  • KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
  • "We look forward to sharing for the first time the results of our Phase 1 study of KSI-501ABC, our anti-IL-6 antibody and VEGF-trap bispecific therapeutic candidate in its antibody biopolymer conjugate form.
  • We believe these early results support further clinical development of the KSI-501 program," said Dr. J. Pablo Velazquez-Martin, MD., Senior Vice President of Clinical Research and Development.